Literature DB >> 9761295

A new model of proliferative vitreoretinopathy.

E M Frenzel1, K A Neely, A W Walsh, J D Cameron, D S Gregerson.   

Abstract

PURPOSE: To design a new model of proliferative vitreoretinopathy (PVR) that would not rely on the addition of exogenous cells. The release of endogenous cells from surrounding attachments seems to be an early event in the pathogenesis of PVR. Because the proteolytic enzyme dispase dissociates tissues, the hypothesis was that an intraocular injection of dispase could trigger events that would cause PVR. The requirement for a surgical retinal break at the time of dispase injection was also examined.
METHODS: One eye of Dutch Belted rabbits was injected with 0.003 U to 1.0 U dispase in the subretinal space or vitreous cavity. Control rabbits received a saline injection. An intentional retinal tear was created in animals in some groups. Observations were made for at least 10 weeks after surgery.
RESULTS: Proliferative vitreoretinopathy developed in response to subretinal or intravitreal dispase, with or without creation of a controlled retinal break. Increased severity of PVR correlated with increasing doses of dispase. Evidence of PVR included preretinal membranes, distortion of myelin wings and retinal vessels, fixed retinal folds, and traction retinal detachment. Proliferative vitreoretinopathy did not develop in saline-treated control animals.
CONCLUSIONS: Dispase initiated the development of PVR without the addition of exogenous cells, growth factors, or cytokines typically found in PVR membranes. A cascade of events was probably triggered by dispase, causing native cells and factors to produce PVR. The dispase model of PVR was technically easy to perform, permitted a clear view of the retina, and had a high success rate in development of PVR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9761295

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

2.  Connective tissue growth factor as a mediator of intraocular fibrosis.

Authors:  Shikun He; Youxin Chen; Rima Khankan; Ernesto Barron; Richard Burton; Danhong Zhu; Stephen J Ryan; Noelynn Oliver; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

3.  Catalytic nucleic acid enzymes for the study and development of therapies in the central nervous system: Review Article.

Authors:  Richard Tritz; Cellia Habita; Joan M Robbins; German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2005

4.  The inhibitory effect of small interference RNA protein kinase C-alpha on the experimental proliferative vitreoretinopathy induced by dispase in mice.

Authors:  Qianying Gao; Wencong Wang; Yuqing Lan; Xiaoqing Chen; Wei Yang; Yongguang Yuan; Juan Tan; Yao Zong; Zhaoxin Jiang
Journal:  Int J Nanomedicine       Date:  2013-04-19

5.  Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review.

Authors:  Eric W Schneider; Mark W Johnson
Journal:  Clin Ophthalmol       Date:  2011-08-18

6.  Pharmacologic vitreolysis.

Authors:  Hossein Nazari; Mehdi Modarres-Zadeh; Arash Maleki
Journal:  J Ophthalmic Vis Res       Date:  2010-01

7.  Ocular pathogenesis and immune reaction after intravitreal dispase injection in mice.

Authors:  Juan Tan; Yaqin Liu; Wei Li; Qianying Gao
Journal:  Mol Vis       Date:  2012-04-07       Impact factor: 2.367

8.  Assessment of the innate and adaptive immune system in proliferative vitreoretinopathy.

Authors:  W Zhang; J Tan; Y Liu; W Li; Q Gao; P V Lehmann
Journal:  Eye (Lond)       Date:  2012-03-30       Impact factor: 3.775

9.  Substance P prevents development of proliferative vitreoretinopathy in mice by modulating TNF-α.

Authors:  Kyungsang Yoo; Bo Kwon Son; Suna Kim; Youngsook Son; Seung-Young Yu; Hyun Sook Hong
Journal:  Mol Vis       Date:  2017-12-13       Impact factor: 2.367

10.  The impact of octreotide in experimental proliferative vitreoretinopathy.

Authors:  Ozge Evren; Burak Turgut; Ulku Celiker; Kadir Ates
Journal:  Indian J Ophthalmol       Date:  2013-03       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.